Sclerosis News and Research RSS Feed - Sclerosis News and Research

Study: Extending natalizumab treatment effective in preventing MS symptoms

Study: Extending natalizumab treatment effective in preventing MS symptoms

In a study of 1,964 patients with multiple sclerosis (MS) led by researchers at the NYU Langone Multiple Sclerosis Comprehensive Care Center, extending the dose of natalizumab from 4 weeks up to 8 weeks was shown to be well-tolerated and effective in patients, and resulted in no cases of the potentially fatal side effect progressive multifocal leukoencephalopathy (PML). [More]
Two existing drugs may reverse damage caused by multiple sclerosis

Two existing drugs may reverse damage caused by multiple sclerosis

A pair of topical medicines already alleviating skin conditions each may prove to have another, even more compelling use: instructing stem cells in the brain to reverse damage caused by multiple sclerosis. [More]
New OCT angiography can improve clinical management of leading causes of blindness

New OCT angiography can improve clinical management of leading causes of blindness

Research published today in the Proceedings of the National Academy of Sciences demonstrates that technology invented by researchers at Oregon Health & Science University's Casey Eye Institute can improve the clinical management of the leading causes of blindness. [More]
Two existing drugs may potentially become new drug target for multiple sclerosis

Two existing drugs may potentially become new drug target for multiple sclerosis

Two drugs already on the market -- an antifungal and a steroid -- may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis. [More]
Tackling the challenge of managing fatigue in MS patients

Tackling the challenge of managing fatigue in MS patients

Fatigue is one of the most commonly reported and debilitating symptoms of multiple sclerosis (MS) and can significantly reduce an individual's quality of life. Unlike the tiredness that we all experience sometimes, fatigue in those with MS can have a hugely negative impact - it can limit or stop people from doing day-to-day activities and things that really matter to them. [More]
Study shows epilepsy drug can protect vision of MS patients

Study shows epilepsy drug can protect vision of MS patients

A drug commonly taken to prevent seizures in epilepsy may surprisingly protect the eyesight of people with multiple sclerosis (MS), according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015. [More]
New research links sleep apnea, heavy snoring with premature cognitive decline

New research links sleep apnea, heavy snoring with premature cognitive decline

Heavy snoring and sleep apnea may be linked to memory and thinking decline at an earlier age, according to a new study published in the April 15, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
MEMREHAB trial shows that treatment with mSMT may be adversely affected by cognitive dysfunction

MEMREHAB trial shows that treatment with mSMT may be adversely affected by cognitive dysfunction

Kessler Foundation researchers published a subanalysis of their MEMREHAB trial, which shows that treatment with the modified Story Memory Technique (mSMT) may be affected by cognitive dysfunction. Investigators looked at the influence of processing speed on benefits of the mSMT, a 10-session cognitive intervention protocol shown to improve new learning and memory in individuals with MS. [More]
Arts and craft activities, computer use may stave off memory problems

Arts and craft activities, computer use may stave off memory problems

People who participate in arts and craft activities and who socialize in middle and old age may delay the development in very old age of the thinking and memory problems that often lead to dementia, according to a new study published in the April 8, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Children who eat certain types of food more likely to contract Epstein-Barr virus

Children who eat certain types of food more likely to contract Epstein-Barr virus

A new study by UNC Charlotte scholars is shedding light on the connection between diet and a common childhood disease. [More]
National MS Society commits $28 million to support new MS research projects, training awards

National MS Society commits $28 million to support new MS research projects, training awards

The National Multiple Sclerosis Society has committed $28 million to support an expected 84 new MS research projects and training awards. These are part of a comprehensive research strategy aimed at stopping MS, restoring function that has been lost, and ending the disease forever – for every single person with MS. [More]
Researchers explore influence of low-frequency magnetic fields on neurodegenerative disorders

Researchers explore influence of low-frequency magnetic fields on neurodegenerative disorders

Low-frequency alternating magnetic fields such as those generated by overhead power lines are considered a potential health risk because epidemiological studies indicate that they may aggravate, among other things, neurodegenerative disorders such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS). [More]
Aging associated with development of dysphagia

Aging associated with development of dysphagia

Nearly 40 percent of Americans 60 and older are living with a swallowing disorder known as dysphagia. Although it is a major health problem associated with aging, it is unknown whether the condition is a natural part of healthy aging or if it is caused by an age-related disease that has yet to be diagnosed, such as Parkinson's disease or amyotrophic lateral sclerosis (ALS). [More]
Antibodies may trigger psychiatric illness in children

Antibodies may trigger psychiatric illness in children

A world first study revealing the presence of two antibodies in a sub-group of children experiencing their first episode of psychosis affirms a longstanding recognition that auto-immune disorders play a significant role in psychiatric illness. [More]
Patient's own skin cells may hold key to new treatments for neurological diseases

Patient's own skin cells may hold key to new treatments for neurological diseases

A patient's very own skin cells may hold the key to new treatments and even cures for devastating neurological diseases. A generous $1 million donation from Mr. J. Sebastian van Berkom, and critical partnerships with Brain Canada, Laval University, Marigold Foundation and the FRQS-Réseau Parkinson Quebec are driving an innovative, iPSC (induced pluripotent stem cell) research platform that will transform research into Parkinson's and other neurological diseases. [More]
Study provides insights into basis for cognitive dysfunction

Study provides insights into basis for cognitive dysfunction

Scientists at Columbia University's Mailman School of Public Health have identified a unique pattern of immune molecules in the cerebrospinal fluid of people with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) that provides insights into the basis for cognitive dysfunction--frequently described by patients as "brain fog"--as well as new hope for improvements in diagnosis and treatment. [More]
Study finds link between neurodegenerative disorders and inflammation

Study finds link between neurodegenerative disorders and inflammation

Researchers from McMaster University and the Icahn School of Medicine at Mount Sinai, New York have discovered that a protein associated with neurodegenerative diseases like ALS also plays an important role in the body's natural antiviral response. [More]
Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Merck Serono, Intrexon partner to develop and commercialize CAR-T cancer therapies

Merck Serono, the biopharmaceutical business of Merck, and Intrexon Corporation, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. [More]
Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint. [More]
Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI). [More]
Advertisement
Advertisement